Abstract
The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P
| Original language | English |
|---|---|
| Pages (from-to) | 1064-1071 |
| Number of pages | 8 |
| Journal | Movement Disorders |
| Volume | 28 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Jul 2013 |
Fingerprint
Keywords
- Dyskinesia
- Entacapone
- Levodopa
- Parkinson's disease
- Wearing-off
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. / Warren Olanow, C.; Kieburtz, Karl; Rascol, Olivier; Poewe, Werner; Schapira, Anthony H.; Emre, Murat; Nissinen, Helena; Leinonen, Mika; Stocchi, Fabrizio.
In: Movement Disorders, Vol. 28, No. 8, 07.2013, p. 1064-1071.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
AU - Warren Olanow, C.
AU - Kieburtz, Karl
AU - Rascol, Olivier
AU - Poewe, Werner
AU - Schapira, Anthony H.
AU - Emre, Murat
AU - Nissinen, Helena
AU - Leinonen, Mika
AU - Stocchi, Fabrizio
PY - 2013/7
Y1 - 2013/7
N2 - The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P
AB - The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P
KW - Dyskinesia
KW - Entacapone
KW - Levodopa
KW - Parkinson's disease
KW - Wearing-off
UR - http://www.scopus.com/inward/record.url?scp=84881558752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881558752&partnerID=8YFLogxK
U2 - 10.1002/mds.25364
DO - 10.1002/mds.25364
M3 - Article
C2 - 23630119
AN - SCOPUS:84881558752
VL - 28
SP - 1064
EP - 1071
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 8
ER -